Biocracked
Conceptual metaphor in a bold color field palette: a single vintage analog wall clock with a plain, unmarked white face, photographed straight on against a saturated mustard-yellow backdrop. The hands are visibly bent and slightly loose, and a thin strip of translucent tape holds the hands at a different position. A small pile of eight tiny brass gears sits at the base, with one gear glowing electric green (#00e676) as the lone accent. Lighting is hard, direct studio flash from the upper left, casting a crisp, graphic shadow of the clock onto the yellow wall. Slight macro depth of field blurs the gears in front. Mood is skeptical, curious and playful, suggesting a claim that deserves scrutiny. Photorealistic, with real metal and glass reflections and no text or numerals.
Supplements

NMN + BHB + Ginsenosides: The '4-Year Younger' Clock Claim, Decoded

Nova Chen · · 4 min read

A supplement stack built on NMN was linked to a roughly 4-year drop in an epigenetic aging clock in about six weeks. That line is made for a product page. The study behind it is more modest, and the authors say so themselves.

The paper, published in Nutrients (2026; DOI 10.3390/nu18213490), tested NMN-based formulations in middle-aged Japanese adults. Here is what it found, what it didn't, and how to read similar claims when you see them on a supplement label.

The Headline Number: ~4.1 Years on DNAm PhenoAge

In a separate, uncontrolled molecular pilot of eight participants, DNAm PhenoAge relative to chronological age decreased by approximately 4.1 years. The pilot also showed nominal transcriptomic changes.

The authors then add a caveat: these exploratory age-related measures "do not establish biological age reversal." The pilot had no control group and only eight people. The abstract also doesn't break down per-participant results or say how much of the shift could be measurement noise.

A drop of about four years on a methylation-based clock is an observation. It is not proof that anyone became biologically younger.

What Was Actually Tested

The main trial was a 42-day, open-label, four-arm exploratory study of 40 Japanese adults aged 45–65 in the final analysis:

  • Placebo: n = 10
  • NMN alone: n = 9
  • Core combination: n = 10
  • Expanded eight-component formulation: n = 11

The combinations built on NMN (a nicotinamide adenine dinucleotide, or NAD+, precursor) with β-hydroxybutyrate (BHB), ginsenosides, and what the authors call "complementary metabolic modulators." The abstract doesn't list all eight components or their doses, so this article doesn't either.

Participants had cardiopulmonary exercise testing (CPET) and computerized cognitive assessments (CogniTrax) at baseline and week 6. Exploratory work added immune and inflammatory biomarkers and model-derived functional-age estimates for a placebo-versus-expanded-formulation subset.

The Fine Print That Matters

No significant between-group wins on the main outcomes

This is the most important sentence in the abstract. Between-group comparisons did not demonstrate statistically significant improvements in the selected cardiopulmonary or cognitive outcomes. The authors say the work does not establish clinical efficacy or ingredient-specific effects.

Descriptive cognitive differences, not proof

The expanded-formulation group did show favorable descriptive changes compared with placebo:

  • Neurocognitive Index: +3.09 vs. −1.90
  • Composite memory: +5.82 vs. −5.30
  • Verbal memory: +9.00 vs. −2.50

With about 10 people per arm, and no significance in the formal comparisons, these numbers can swing on a few individuals. In an open-label design, participants know what they are taking, and expectation can influence cognitive test performance.

Biomarkers with unadjusted p-values

Nominal between-group differences appeared in CTACK (p = 0.015) and GDF-15 (p = 0.022). Neither was adjusted for multiple testing, and the authors state that the direction of change does not establish clinical benefit. When many markers are checked, a few will cross p < 0.05 by chance.

The functional-age composite

A model-derived functional-age composite fell 2.79 years in the expanded-formulation group versus 0.63 years in placebo. It is a modeled estimate built from other measurements, not a direct measure of aging, and it is also labeled exploratory.

Safety and adherence

On the positive side, the intervention was associated with high recorded adherence and no reported serious adverse events. That supports the feasibility the authors claim, but a six-week study with 40 people can't answer long-term safety questions.

Who Funded and Formulated This?

The disclosures are worth knowing. Abe Yoando Pharmaceutical Co., Ltd. developed and provided the study formulations. The conflict-of-interest statement also notes that supplied project materials state a patent application (No. 2025-079089) has been filed concerning NMN+BHB-related muscle, cognitive, and anti-inflammatory effects. One listed author was employed by SOUKEN Co., Ltd.

This doesn't invalidate the work. The authors are open about the study's limits. But a company with a patent filing and a product stake is a reason to ask for independent replication.

Practical Takeaways

1. Read "open-label" as "everyone knew." Participants and investigators weren't blinded, so expectation effects and subjective bias can't be separated from any real effect.

2. Small arms limit conclusions. With 9–11 people per group, one unusual responder can change an average. Descriptive differences like +9.00 vs. −2.50 are hypothesis fodder, not results.

3. An uncontrolled clock pilot can't show cause. Without a comparison group, a 4.1-year PhenoAge shift can't be separated from test-retest variability, lifestyle changes, or the placebo effect. Eight participants is too few to say what a typical person would see.

4. Know what an epigenetic clock is. DNAm PhenoAge is a methylation-based estimate trained to predict health-related outcomes. Moving the number is not the same as changing your actual risk of disease or death. Marketing that says "X years younger" skips that gap.

5. Spot the red flags on supplement pages. Look for:

  • a clock result with no control group
  • an n that isn't stated
  • "reverse aging" language
  • p-values cited without mention of multiple testing
  • a stack of eight ingredients presented as if each one were proven

The authors themselves say the study cannot establish ingredient-specific effects. Any marketing that credits NMN, BHB, or ginsenosides individually goes beyond what this paper shows.

6. Who might reasonably experiment? This study doesn't make a recommendation. Healthy adults curious about NAD+-related supplements may reasonably wait for randomized, double-blind data. Anyone with a medical condition or on medication should talk to a clinician before adding a multi-ingredient stack, especially one whose components and doses aren't fully disclosed. If you do try something, track objective measures with a clinician's help rather than relying on a single clock number.

Bottom Line

This is a feasibility-stage study, not a breakthrough. It suggests that six weeks of an NMN-based stack was tolerable and generated some interesting signals in cognition, inflammation markers, and methylation. It does not show that the stack works, that any one ingredient is responsible, or that anyone's biological age was reversed. The authors call for larger randomized, double-blind trials with prespecified outcomes. Until those arrive, treat the four-year headline as a question to test, not a result.

Original study

Read the original research on pubmed.ncbi.nlm.nih.gov →

This article summarizes published research for general information. It is not medical advice.

NC

Written by

Nova Chen

Nova Chen writes for Biocracked: biohacking science, longevity & human performance.

Related Articles

Approach: Lab in action. Palette: B, warm.

Close, slightly high three-quarter angle on an isolated rat heart suspended in a Langendorff perfusion rig, the small dark-red heart held by its aorta on a glass cannula inside a warm-jacketed glass chamber. Clear perfusion fluid drips from the heart and beads on the glass. A gloved hand in the soft-focus foreground adjusts a stopcock. Amber, honey-colored light from a low side lamp rakes across the curved glass, producing copper highlights and warm brown shadows. Behind it, a blurred bench holds tubing and a small pressure transducer. A thin electric green (#00e676) indicator light glows on the instrument at the edge of the frame. Mood: quiet, focused, cautiously hopeful, with real laboratory texture and shallow depth of field. No text or labels.
longevity

Two Popular Supplements Shielded Old Rat Hearts. Here's the Catch

BY DR. SYNAPSE ·

A new rat study found that pairing NMN with melatonin helped aged hearts recover from a heart-attack-style injury better than either compound alone. Treated hearts showed improved coronary flow and pressure recovery, along with lower creatine kinase and inflammatory markers. But the work was done on isolated rat hearts, with melatonin delivered in the perfusion fluid and NMN given by injection. That means it says nothing yet about taking supplements as pills or about human benefit. Here is what the researchers did, what they found, and why it is only a first step.

Approach 1, macro science, in palette D, bold color field.

Extreme close-up microscopy-style image of a single mouse oocyte, a translucent spherical egg, shot straight on at its equator. Inside the cytoplasm, hundreds of mitochondria appear as tiny glowing grains. Most are a muted grey-amber, while a scattered subset of small and large organelles glows vivid electric green (#00e676), clustered unevenly to suggest an uneven response. Fine granular cumulus cells cling to the egg's edge, slightly out of focus. The backdrop is a saturated, flat magenta-violet field, with soft rim light wrapping the egg's glassy membrane and shallow depth of field blurring the edges. The mood is quiet, precise and slightly uneasy, a closer look revealing what the averages hid. Photoreal confocal-meets-studio look, with no text and no labels.
longevity

NMN Rejuvenated Hidden Mitochondria in Aged Eggs, But Not Evenly

BY NOVA CHEN ·

Aged mouse eggs looked mitochondrially normal on average, but a new single-organelle study says the averages were hiding something. Specific subpopulations, high-membrane-potential and small mitochondria, carried elevated mtDNA copy number with age. NMN pulled those back toward young levels, yet pushed large mitochondria the opposite way, and in surrounding cumulus cells it overshot young levels in some groups. No fertility or pregnancy outcomes were measured, the work was in mice, and some authors have patent and company ties. Here is what it means, and does not mean, for women weighing NMN for fertility.

Approach: Macro science (tissue). Palette: B, warm.

Extreme macro photograph in the style of a microscopy image, showing a cluster of rounded, translucent golden fat cells (adipocytes) in the foreground. Fine strands of pale pink-red muscle fibers run diagonally across the frame behind them. Between the two tissues, tiny glistening droplets drift along a thin capillary, suggesting a signal travelling from fat to muscle. Shot at a slight low angle with shallow depth of field, so the foreground cells are crisp and the muscle fibers melt into soft blur. Lit by warm amber backlight that makes the fat cells glow like honey, with copper-toned shadows and a faint rim of light on the fiber edges. One small electric green fluorescent speck sits inside a single droplet as the only cool accent. The mood is quiet, curious and intimate, with a sense of hidden communication inside the body.
longevity

The Fat-Derived Messenger That May Shield Muscle When NAD+ Rises

BY NOVA CHEN ·

Most people who take NMN or NR assume the NAD+ boost works directly inside muscle. A new mouse study in Cell Metabolism suggests fat tissue may be a hidden middleman, releasing a protective protein called Serpina3n into the blood. That signal protected muscle in models of aging, disuse and cancer cachexia, apparently by preserving a key metabolic enzyme. But this is animal research, the authors have filed a patent, and nothing here establishes benefits or doses for human supplement users. Here is what it does and doesn't mean for your routine.

Approach 4, conceptual metaphor, in palette D, bold color field.

A single glass beaker-shaped water carafe sits at center frame on a saturated tangerine-orange seamless backdrop, photographed straight-on at slight low angle. The carafe is filled with clear water, and a small, cleanly drilled hole near its base releases a thin, steady stream that falls into a shallow white ceramic dish below, with a few droplets frozen mid-air. This stands for NAD+ draining away through a leak. A tiny electric green (#00e676) rubber stopper is held by a gloved fingertip entering from the right, about to plug the hole. Lighting is crisp, high-key studio light from upper left, giving sharp specular highlights on the glass and soft, warm-neutral shadows on the backdrop. Mood: clever, precise, optimistic but skeptical. No text or labels.
longevity

The NAD+ Thief in Your Brain: Blocking CD38 Raised Brain NAD+

BY NOVA CHEN ·

Everyone talks about boosting NAD+, but a new preclinical study spotlights the enzyme that may be draining it: CD38. A brain-penetrant inhibitor called CVN14 raised brain NAD+ in rats and mice, and it did nothing in mice lacking CD38. In Parkinson's models, it was linked to better dopaminergic neuron survival in culture and improved motor function in rats. But this is an experimental drug from Cerevance, tested in animals and cells, and all authors work for the company. Here is what it does and does not mean for NMN and NR buyers.

This page is available in